<DOC>
	<DOCNO>NCT01772563</DOCNO>
	<brief_summary>The primary objective present study investigate influence co-administration itraconazole volasertib pharmacokinetic profile volasertib without co-administration itraconazole . Secondary objective investigate safety , tolerability preliminary therapeutic effect follow intravenous administration volasertib .</brief_summary>
	<brief_title>Investigation Potential Drug-drug Interaction Volasertib With Itraconazole Patients With Various Tumours</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm diagnosis advance , non resectable / metastatic solid tumour , conventional treatment fail , therapy proven efficacy exists , amenable establish form treatment base investigator 's assessment 2 . Male female 3 . Age = &gt; 18 = &lt; 70 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score = &lt; 2 5 . Recovery Common Terminology Criteria Adverse Events ( CTCAE ) Grade &gt; = 2 therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy ( except alopecia ) Exclusion criterion : 1 . Serious concomitant nononcological disease consider investigator incompatible protocol 2 . Active infectious disease 3 . Viral hepatitis , HIV infection 4 . Clinical evidence active brain metastasis leptomeningeal disease past 6 month 5 . Second malignancy currently require active therapy ( except hormonal / antihormonal treatment e.g . prostate breast cancer ) 6 . Absolute neutrophil count less 1,500/mm3 7 . Platelet count less 100,000/mm3 8 . Total bilirubin great 1.5 mg/dL ( &gt; 26 Âµmol/L , SI unit equivalent ) 9 . Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) 10 . Serum creatinine great 2x upper limit normal ( ULN ) 11 . QTcF prolongation &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) .The QTcF calculate mean 3 ECGs take screen 12 . Female patient childbearing potential unwilling use medically acceptable method contraception trial least six month end active therapy . Woman childbearing potential ( premenopausal female ) define female surgically sterilised hysterectomy bilateral tubal ligation postmenopausal least 12 month . 13 . Treatment investigational drug participation another clinical trial within past four week prior start therapy concomitantly trial 14 . Chemo , radio immuno , moleculartargeted cancertherapy within past four week prior start therapy concomitantly trial . This restriction apply steroid , bisphosphonates hormonal / antihormonal treatment ( e.g . prostate breast cancer ) . 15 . Alcohol abuse average 3 unit alcoholic beverage per day 21 unit per week ( 1 unit equal 0.5 pint [ 285 mL ] beer lager , 1 glass [ 125 mL ] wine , 25 mL shoot 40 % spirit ) drug abuse 16 . Life expectancy le 12 week 17 . Potent CYP 3A4 Pglycoprotein inhibitor study drug inducer one week prior first drug administration expect treatment respective drug last PK sample collect 1 . Strong CYP 3A4 inhibitor : atazanavir , clarithromycin , indinavir , itraconazole ( study drug ) , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin 2 . CYP 3A4 inducer : carbamazepine , rifampicin 3 . Pgp inhibitor : cyclosporine , erythromycin , itraconazole ( study drug ) , ketoconazole , quinidine , phenobarbital salt quinidine , ritonavir , valspodar , verapamil 4 . Pgp inducer : hypericum perforatum , rifampicin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>